Skip to content
LATEST
Health

Nonprofit Partnership Targets Drug Repurposing for 14,000 Untreated Diseases

Every Cure and OpenEvidence have partnered to use AI and specialist networks to repurpose existing drugs for 14,000 rare diseases currently lacking approved…

Nonprofit Partnership Targets Drug Repurposing for 14,000 Untreated Diseases

A new partnership between Every Cure and OpenEvidence aims to accelerate the identification and clinical validation of existing medications for diseases lacking commercial treatment options. The initiative focuses on approximately 14,000 recognized conditions that currently lack FDA-approved therapies, affecting an estimated 300 million people globally. By leveraging existing safety data and established manufacturing pipelines, the collaboration seeks to bypass the high costs and extended timelines associated with traditional de novo drug development.

The operational model utilizes artificial intelligence to systematically evaluate approved drugs against specific disease profiles. OpenEvidence will provide proprietary biomedical models and data, including access to peer-reviewed research, to refine these repurposing hypotheses. A critical component of the strategy involves identifying and engaging the limited number of specialists who treat rare diseases to ensure research questions and study designs align with clinical realities.

Every Cure

Beyond research, the partnership addresses systemic barriers in clinical trial recruitment and evidence dissemination. OpenEvidence will facilitate the identification of potential trial candidates by alerting treating physicians to relevant studies, thereby streamlining patient enrollment for rare disease research. Once clinical data is generated, the platform will distribute findings directly to clinicians at the point of care to support evidence-based treatment decisions.

The success of this initiative depends on the ability to translate AI-generated hypotheses into verified clinical evidence. While the nonprofit structure avoids the requirement for traditional commercial returns, the project must still meet rigorous safety and efficacy standards to achieve regulatory and clinical acceptance. The collaboration integrates Every Cure’s experience in drug repurposing with a broad network of U.S. physicians to bridge the gap between theoretical research and patient access.

More stories

Latest news